<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301001</url>
  </required_header>
  <id_info>
    <org_study_id>10-00985-FB CSBrown Vulvodynia</org_study_id>
    <nct_id>NCT01301001</nct_id>
  </id_info>
  <brief_title>A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response</brief_title>
  <official_title>A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tennessee Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Specific aims of this project are to (1) test the prediction that pain from tampon
      insertion (primary outcome measure) is lower in PVD patients when treated with gabapentin
      compared to when treated with placebo. Secondary outcome measures include intercourse pain
      and 24-hour pain and (2)perform a mechanism-based analysis of gabapentin effectiveness, and
      to gain insight into the underlying pathophysiology of subtypes of PVD that may lead to more
      specific treatment options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 18-week, randomized, double-blind, placebo-controlled, two-treatment, two-period
      crossover design, where 120 women between 18 of age and older who report insertional
      dyspareunia, pain with tampon insertion, and tenderness localized to the vulvar vestibule
      will be enrolled in the study. Electronically entered daily diaries will be used to determine
      if pain is lower in PVD subjects when treated with gabapentin (up to 3600 mg/d) compared to
      when treated with placebo. Biological measurements will include assessment of allodynia and
      hyperalgesia from capsaicin administration, muscle tension using a vaginal pressure
      algometer, number of tender points by clinical examination, and changes in blood pressure,
      pulse and heart rate variability. . The Long-range goals of this project are to explicate the
      underlying pathophysiologic mechanisms of PVD, and to use this knowledge to create
      evidence-based differential diagnoses of subtypes of PVD and to individualize treatments for
      each subtype. The immediate goal is to conduct a multicenter, randomized controlled trial
      (RCT) of gabapentin treatment for PVD, and which will also provide critical data on a new
      PVD-testing and response paradigm, as well as on characteristics that may define subtypes of
      PVD. Gabapentin, an anticonvulsant with analgesic, anxiolytic, and antispasmotic effects, was
      selected because of its efficacy in treating other neuropathic pain conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tampon Test Pain Intensity</measure>
    <time_frame>Week 6 for each treatment arm</time_frame>
    <description>Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coital Pain</measure>
    <time_frame>Week 6 of each treatment arm</time_frame>
    <description>Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vulvodynia Pain</measure>
    <time_frame>Week 6 for each treatment arm</time_frame>
    <description>Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Vulvodynia</condition>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo 2 capsules am and 3 capsules pm</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 1200 mg am and 1800 mg pm</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Gralise 600 mg capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women who are 18 years of age and older, as long as no vaginal atrophy is present. If
             vaginal atrophy is present, then topical hormone replacement can be provided for a
             minimum of 6 weeks and then she must be re-screened to be eligible,

          2. Greater than 3 continuous months of insertional (entryway) dyspareunia, pain to touch,
             or both with tampon insertion (modified 'Friedrich's Criteria', and

          3. an average pain level of &quot;4&quot; or greater on the 11-point tampon test (0 = no pain at
             all; 10 = worse pain ever) during the 2-week screening period must be exhibited.

        (One tampon will be inserted each week). 4.) Must report pain with the &quot;Tampon Insertion
        Pain&quot; Test at visit 1

        Exclusion Criteria:

          1. Other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, or
             atrophic vaginitis (presence of a maturation index)

          2. previous vestibulotomy

          3. active vaginal infection (positive Affirm ™ VPIII microbial identification test)

          4. pregnancy or at risk for pregnancy and not using a reliable birth control method for
             at least 3 months prior to entering the study

          5. any unstable medical condition, including renal impairment (creatinine clearance of
             ≤60 mL/min, BUN &gt; 30mg/dL, serum creatinine &gt; 2 mg/dL), significant hematological
             disease (leukopenia [WBC &lt; 3.0 x 10-3µl, leukocytosis [WBC &gt;20.0 x 10-3μl],
             neutropenia [ABS &lt; 1.50 x 10-3 μl, &lt;20%]), (thrombocytopenia [platelets &lt; 100,000 μl],
             anemia [HCT &lt; 27%, HBG &lt;8 g/dL, RBC &lt;3 x 10-6]), cardiovascular disease (cardiac
             conduction disturbance, CHF, hypertension [140/90]), hepatic insufficiency (serum AST,
             ALT, or ALP ≥ 3 times upper limit of normal), neurological disorder (seizures,
             syncopal episodes, peripheral neuropathy, severe pain other than that caused by
             vulvodynia), autoimmune disease, or respiratory illness

          6. psychiatric disorder, including history of major depressive disorder or substance
             abuse disorder within the past 6 months, a score of &gt; 12 on the depression subscale of
             the Hospital Anxiety and Depression Scale (HADS), indicting a major depressive episode
             (35,36), a serious risk of suicide, or lifetime history of psychosis, hypomania or
             mania

          7. multiple allergies

          8. use of benzodiazepines, opiates, muscle relaxants, tricyclic antidepressants (TCAs),
             serotonin-norepinephrine reuptake inhibitors (SNRIs) or CNS stimulants (including
             methylphenidate, amphetamine dextroamphetamine) within 2 weeks of randomization and
             during the study

          9. use of certain herbal agents within 2 weeks of randomization and during the study,
             including ginkgo biloba, evening primrose, St. John's Wort, Valerian, kava kava)

         10. topical lidocaine use

         11. Subjects, who are diagnosed with coexisting vaginismus, fibromyalgia and/or
             interstitial cystitis, must have greater vulvar pain than their coexisting conditions
             or they will not be eligible for study participation

         12. Subject who have previously taken gabapentin or Lyrica but discontinued the medication
             due to side effects are not eligible

         13. Subjects with active infections (Candida, BV, trichomonas, chlamydia, GC and HSV via
             Affirm/culture) must be treated and re-screened to eligible for participation

         14. Subjects with 10% or greater parabasal cells and/or vaginal atrophy can be provided
             with topical hormone replacement for a minimum of 6 weeks and then must be re-screened
             to be eligible

         15. Subjects who have had gastric bypass surgery are ineligible for study participation
             due to drug absorption problems

         16. HPV/abnormal Pap is not exclusionary

         17. Ongoing counseling and/or physical therapy is not exclusionary

         18. Subjects who report signs of mixed Vulvodynia (spontaneous/provoked, localized,
             generalized) during prescreening will not be excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candace S Brown, MSN, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David C Foster, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester School of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gloria A Bachmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Robert Wood Johnson Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901-1962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester School of Medicine and Dentistry</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hopeformypain.org</url>
    <description>Web link for study information and Pre-screening questionnaire</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <results_first_submitted>August 28, 2017</results_first_submitted>
  <results_first_submitted_qc>November 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2017</results_first_posted>
  <disposition_first_submitted>May 5, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>July 11, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 13, 2017</disposition_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvodynia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvodynia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between August 8, 2012 and January 19, 2016 from three academic centers.</recruitment_details>
      <pre_assignment_details>230 women were screened, 89 met entry criteria and 66 completed the trial. Of the 141 patients who were excluded prior to randomization, 16 decided not to participate in the trial,101 did not meet inclusion criteria, and 24 did not return for randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First, Then Gabepentin</title>
          <description>Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
Placebo oral capsule: Placebo 2 capsules am and 3 capsules pm
Gabapentin: Gabapentin 1200 mg am and 1800 mg pm</description>
        </group>
        <group group_id="P2">
          <title>Gabapentin First, Then Placebo</title>
          <description>Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
Placebo oral capsule: Placebo 2 capsules am and 3 capsules pm
Gabapentin: Gabapentin 1200 mg am and 1800 mg pm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>44 subjects were randomized to Placebo First and 45 subjects were randomized to Gabapentin First</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.54" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tampon Test Pain Intensity</title>
        <description>Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days).</description>
        <time_frame>Week 6 for each treatment arm</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules am and 3 capsules pm</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>2 capsules (1200 mg) am and 3 capsules (1800 mg) pm</description>
          </group>
        </group_list>
        <measure>
          <title>Tampon Test Pain Intensity</title>
          <description>Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). One tampon was inserted each week. Tampon pain was assessed during last week of maintenance phase (7 days).</description>
          <population>Intention to Treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" lower_limit="3.37" upper_limit="5.22"/>
                    <measurement group_id="O2" value="3.96" lower_limit="3.03" upper_limit="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coital Pain</title>
        <description>Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm.</description>
        <time_frame>Week 6 of each treatment arm</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules am and 3 capsules pm</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg am and 1800 mg pm</description>
          </group>
        </group_list>
        <measure>
          <title>Coital Pain</title>
          <description>Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event. The number of sexual intercourse events was averaged during final week of each treatment arm.</description>
          <population>Intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="2.50" upper_limit="5.44"/>
                    <measurement group_id="O2" value="3.85" lower_limit="2.36" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vulvodynia Pain</title>
        <description>Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged.</description>
        <time_frame>Week 6 for each treatment arm</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>2 capsules am and 3 capsules pm</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>1200 mg am and 1800 mg pm</description>
          </group>
        </group_list>
        <measure>
          <title>Vulvodynia Pain</title>
          <description>Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever). Pain was assessed daily during the last week of treatment. Daily scores were averaged.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" lower_limit="1.99" upper_limit="3.76"/>
                    <measurement group_id="O2" value="2.71" lower_limit="1.82" upper_limit="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>Definition of adverse events is the same as clinicaltrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>2 capsules am and 3 capsules pm</description>
        </group>
        <group group_id="E2">
          <title>Gabapentin</title>
          <description>2 capsules (1200 mg) am and 3 capsules (1800) mg pm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>unstable angina and malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cluster headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma with acute exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Bacterial Vaginosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Candace Brown</name_or_title>
      <organization>University of Tennessee Health Science Center</organization>
      <phone>9014124341</phone>
      <email>CSBROWN@TENNESSEE.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

